() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Blissco Selected to Present at Sick Kids Hospital on Canadian Childhood Cannabinoid Clinical Trials

Blissco Selected to Present at Sick Kids Hospital on Canadian Childhood Cannabinoid Clinical Trials

Not for distribution in the U.S. or to U.S. Newswires

VANCOUVER, British Columbia, Feb. 27, 2019 (GLOBE NEWSWIRE) --  Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B), (“Blissco”) or the (“Company”) is a Canadian wellness cannabis brand based in British Columbia and a licensed processor, producer, and distributor of premium dried cannabis and cannabis oil. The Company is pleased to announce that it has been invited to present at the Canadian Childhood Cannabinoid Clinical Trials (C4T) Workshop at Sick Kids Hospital in Toronto on February 27 and 28.

Blissco will provide an industry perspective on cannabis research and development. Five other Canadian licensed producers including, Aurora Cannabis Inc., Canopy Growth Corporation, and Tilray Inc. were also invited to participate.

“I am delighted that Blissco among other industry partners has agreed to support and participate in the C4T Workshop. This is the first time a diverse group of stakeholders interested in cannabinoid pediatric research, represented by research, patients/families, regulators, funders and industry will be under one roof,”

said Stephen Barbazuk, Executive Director of the Maternal Infant Child Youth Research Network (MICYRN).

“We are honored to have the opportunity to support this project. We have a profound personal connection to pediatric hospitals, namely BC Children’s Hospital, and we feel a responsibility to support these clinical trials under the supervision of researchers and doctors to advance solutions for children facing life-threatening illnesses,”

said Damian Kettlewell, Blissco CEO.

Working together, Blissco and the Ernst lab at McGill University and the Douglas Hospital Research Institute will unveil a partnership for pre-clinical research.

“We are proud to partner with Blissco to design and test non-invasive ways to better understand the effects of cannabis in developing human brain cells. IXn-depth pre-clinical research will build the foundation for safe, effective pediatric clinical trials in Canada,”

said Dr. Carl Ernst, Canada Research Chair in Psychiatric Genetics.


The Maternal Infant Child and Youth Research Network is a federal not-for-profit, charitable organization founded in 2006 to build capacity for high-quality applied health research. It now links 20 maternal and child health research organizations based at academic health centres in Canada; is affiliated with more than 20 practice-based research networks; provides support to new and emerging teams; and has established strong national and international partnerships.

A large amount of research is conducted by teams with investigators based at multiple sites across Canada. Working together in a coordinated fashion enables the sharing of innovations and reduces duplication of effort and resource use, which means more funds can be spent on doing research. Learn more at micyrn.ca.

About Blissco Cannabis Corp.

Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B) is a Canadian wellness cannabis brand based in British Columbia and a multi-licensed processor, cultivator and distributor of premium cannabis.

Blissco owns and operates a state-of-the-art GPP facility located in Metro Vancouver, British Columbia with 18,000 square feet of extraction, cultivation and processing rooms. Blissco is supplying premium cannabis and small-batch Reserve whole flower and pre-rolls to the Canadian and global marketplace with a growing list of provincial cannabis boards and international distribution partners.

With a license to process cannabis oil acquired in August 2018, Blissco’s extraction lab is also in operation preparing a line of full spectrum oils for distribution in 2019.

Learn more at blissco.com.

On Behalf of the Board of Directors


Damian Kettlewell, CEO, Founder & Chair

For further information please contact:
1 604 484-9119

Cautionary Statements

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.


Comments are closed.